Surf Wiki
Save to docs
general/peptide-hormones

From Surf Wiki (app.surf) — the open knowledge base

Incretin

Group of gastrointestinal hormones

Incretin

Group of gastrointestinal hormones

GLP-1 and DPP-4 inhibitors

Incretins are a group of metabolic hormones that decrease blood glucose levels. Incretins are released after eating and augment the secretion of insulin released from pancreatic beta cells of the islets of Langerhans by a blood-glucose–dependent mechanism.

Some incretins (GLP-1) also inhibit glucagon release from the alpha cells of the islets of Langerhans. In addition, they slow the rate of absorption of nutrients into the bloodstream by reducing gastric emptying and may reduce food intake. The two main peptides that fulfill criteria for an incretin are the intestinal peptide glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (GIP, also known as: glucose-dependent insulinotropic polypeptide). GIP is produced and secreted into the blood by K cells located in the mucosa of the upper gastrointestinal tract's duodenum and upper jejunum while GLP1 is produced and secreted into the blood by L cells located in the mucosa of the lower gastrointestinal tracts small and large intestines. Short-chain fatty acids (primarily acetic, propionic, and butyric acids), which microganisms form in the intestines, bind to the FFAR2 and FFAR3 receptors on K cells and L cells to stimulate their respective production and secretion of GIP and GLP-1. Both GLP-1 and GIP are inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4) and are members of the glucagon peptide superfamily.

Medical uses

Medications based on incretins are used in the treatment of type 2 diabetes mellitus as well as the management of obesity.

Most of the earliest incretin-targeting agents to be approved fell into the class of DPP-4 inhibitors; these inhibit DPP-4 and prevent the enzymatic degradation of GLP-1 and GIP. The first medication in this class, sitagliptin, received FDA approval in 2006 for the treatment of type 2 diabetes.

GLP-1 analogs principally act as agonists of the GLP-1 receptor and are thus insulinotropic. Exenatide was the first drug in this class to be used in the treatment of type 2 diabetes; it received FDA approval in 2005. More recently, longer-acting and more potent GLP-1 analogs have been developed, most notably semaglutide, which received FDA approval for type 2 diabetes in 2017. It was subsequently approved for the management of obesity. In 2021, it was in the Top 100 most-prescribed drugs in the United States.

Tirzepatide (sold as Mounjaro and Zepbound) is a potent GIP analog with agonist activity at GIP and GLP-1 receptors. It was approved for the treatment of type 2 diabetes in the United States in May 2022, and for the management of obesity in November 2023.

Effect

The incretin effect describes the phenomenon whereby oral glucose intake elicits a higher insulin response compared to intravenously introduced glucose that produces the same levels of serum glucose levels.

History

In 1932, Belgian physiologist Jean La Barre used the word "incretin" for a gut hormone which stimulates the endocrine pancreas including insulin release. He also proposed that such incretins could be used as a treatment for diabetes mellitus.

References

References

  1. (February 2018). "Incretin hormones: Their role in health and disease". Diabetes, Obesity & Metabolism.
  2. (February 2018). "Enteroendocrine K and L cells in healthy and type 2 diabetic individuals". Diabetologia.
  3. (March 2015). "Free fatty acid receptor GPR120 is highly expressed in enteroendocrine K cells of the upper small intestine and has a critical role in GIP secretion after fat ingestion". Endocrinology.
  4. (June 2018). "Probiotics, prebiotics, synbiotics and insulin sensitivity". Nutrition Research Reviews.
  5. (November 2006). "The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes". Lancet.
  6. (July 2007). "Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis". JAMA.
  7. (2016). "Rang and Dale's Pharmacology". Elsevier Churchill Livingstone.
  8. (June 2016). "The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions". The Lancet Diabetes & Endocrinology.
  9. (2018-07-16). "The Origin and Understanding of the Incretin Concept". Frontiers in Endocrinology.
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

peptide-hormones intestinal-hormones gastric-hormones
Want to explore this topic further?

Ask Mako anything about Incretin — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report